Theravance Biopharma to Participate in an Upcoming Investor Conference
Theravance Biopharma (NASDAQ: TBPH) has announced its participation in the H.C. Wainwright 3rd Annual BioConnect Investor Conference in New York City. The company will engage in a Fireside Chat on Tuesday, May 20 at 10:30 AM EDT at NASDAQ. Additionally, TBPH will conduct in-person meetings with the investment community during the conference.
Investors can access the webcast through Theravance's website under the Investors section, Events and Presentations. The webcast recording will remain available for replay on the company's website for 30 days following the event.
Theravance Biopharma (NASDAQ: TBPH) ha annunciato la sua partecipazione alla 3ª Conferenza Annuale BioConnect per Investitori di H.C. Wainwright a New York City. L'azienda prenderà parte a una Fireside Chat il martedì 20 maggio alle 10:30 AM EDT presso il NASDAQ. Inoltre, TBPH terrà incontri in presenza con la comunità degli investitori durante la conferenza.
Gli investitori potranno seguire la diretta streaming sul sito web di Theravance, nella sezione Investitori, sotto Eventi e Presentazioni. La registrazione della diretta sarà disponibile per la visione on demand sul sito aziendale per 30 giorni dopo l'evento.
Theravance Biopharma (NASDAQ: TBPH) ha anunciado su participación en la 3ª Conferencia Anual BioConnect para Inversores de H.C. Wainwright en la ciudad de Nueva York. La compañía participará en una Fireside Chat el martes 20 de mayo a las 10:30 AM EDT en NASDAQ. Además, TBPH realizará reuniones presenciales con la comunidad inversora durante la conferencia.
Los inversores podrán acceder a la transmisión en vivo a través del sitio web de Theravance, en la sección de Inversores, Eventos y Presentaciones. La grabación estará disponible para reproducción durante 30 días posteriores al evento.
Theravance Biopharma (NASDAQ: TBPH)가 뉴욕시에서 열리는 H.C. Wainwright 제3회 연례 BioConnect 투자자 컨퍼런스에 참가한다고 발표했습니다. 회사는 5월 20일 화요일 오전 10시 30분 EDT에 NASDAQ에서 진행되는 Fireside Chat에 참여할 예정입니다. 또한, TBPH는 컨퍼런스 기간 동안 투자자들과의 대면 미팅도 진행할 예정입니다.
투자자들은 Theravance 웹사이트의 투자자 섹션 내 이벤트 및 프레젠테이션에서 웹캐스트를 시청할 수 있습니다. 웹캐스트 녹화는 행사 종료 후 30일간 회사 웹사이트에서 다시보기로 제공됩니다.
Theravance Biopharma (NASDAQ : TBPH) a annoncé sa participation à la 3e conférence annuelle BioConnect pour investisseurs de H.C. Wainwright à New York. La société participera à une discussion informelle (Fireside Chat) le mardi 20 mai à 10h30 EDT au NASDAQ. De plus, TBPH tiendra des réunions en personne avec la communauté des investisseurs durant la conférence.
Les investisseurs pourront accéder au webdiffusion via le site internet de Theravance, dans la section Investisseurs, Événements et Présentations. L’enregistrement restera disponible en replay sur le site de la société pendant 30 jours après l’événement.
Theravance Biopharma (NASDAQ: TBPH) hat seine Teilnahme an der 3. jährlichen BioConnect Investorenkonferenz von H.C. Wainwright in New York City angekündigt. Das Unternehmen wird am Dienstag, den 20. Mai um 10:30 Uhr EDT an einem Fireside Chat am NASDAQ teilnehmen. Zusätzlich wird TBPH während der Konferenz persönliche Treffen mit der Investoren-Community abhalten.
Investoren können den Webcast über die Theravance-Website unter dem Bereich Investoren, Veranstaltungen und Präsentationen verfolgen. Die Aufzeichnung des Webcasts wird für 30 Tage nach der Veranstaltung auf der Unternehmenswebsite verfügbar sein.
- None.
- None.
A webcast of the event may be accessed by visiting Theravance.com, under the Investors section, Events and Presentations. A replay of the webcast will be archived on the Company's website for 30 days.
About Theravance Biopharma
Theravance Biopharma, Inc.'s focus is to deliver Medicines that Make a Difference® in people's lives. In pursuit of its purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Ampreloxetine, its late-stage investigational once-daily norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA), has the potential to be a first in class therapy effective in treating a constellation of cardinal symptoms in MSA patients. The Company is committed to creating/driving shareholder value.
For more information, please visit www.theravance.com.
THERAVANCE BIOPHARMA®, THERAVANCE® and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries).
YUPELRI® is a registered trademark of Mylan Specialty L.P., a Viatris company. Trademarks, trade names or service marks of other companies appearing in this press release are the property of their respective owners.
Contact:
investor.relations@theravance.com
650-808-4045
View original content to download multimedia:https://www.prnewswire.com/news-releases/theravance-biopharma-to-participate-in-an-upcoming-investor-conference-302453476.html
SOURCE Theravance Biopharma, Inc.
FAQ
When is Theravance Biopharma (TBPH) presenting at the H.C. Wainwright BioConnect Conference?
Where can I watch Theravance Biopharma's (TBPH) H.C. Wainwright conference presentation?
What type of presentation will TBPH give at the H.C. Wainwright conference?
How long will TBPH's H.C. Wainwright conference webcast be available for replay?
